AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b

20222023
Written By Guest User
Guest User
Previous

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Next

Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards